Navigation Links
Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment
Date:12/3/2007

PharmaMar, Innovex to build Yondelis(R) sales network across Western Europe

BRACKNELL, United Kingdom, Dec. 3 /PRNewswire/ -- Innovex today announced a services agreement with PharmaMar, a subsidiary of Zeltia SA, to recruit, train and deploy a specialized oncology sales team in Western Europe to promote Yondelis(R), PharmaMar's treatment for soft tissue sarcoma. PharmaMar, which holds the marketing authorization, will be responsible for marketing the drug.

Innovex will initially deploy regional unit heads and key account managers in the United Kingdom, Germany, France, Spain and Italy to promote Yondelis. The project will be coordinated across these countries by PharmaMar and an Innovex European project director.

Innovex, a unit of Quintiles Transnational Corp., is the leading global commercial solutions provider to the pharmaceutical, biotech and medical device industries.

"Innovex's proven ability to build and launch sales forces across a multi- country region was a key factor in PharmaMar's selecting us to build its sales network for Yondelis in Western Europe," said Hywel Evans, Global President, Innovex. "This is testament to our ability to rapidly recruit, train and deploy high-performing specialty sales representatives who ensure our customers achieve their sales objectives."

Yondelis was launched Sept. 19 by PharmaMar in the United Kingdom and Germany, following its approval by the European Medicines Agency for use in the treatment of soft tissue sarcoma.

Alfonso Casal, Commercial Director, PharmaMar, said: "This agreement with Innovex means we can optimize the launch of Yondelis across five Western European countries as registration and reimbursement allows. Innovex has demonstrated that they have the ability to recruit high caliber, experienced oncology representatives that understand the marketplace and have the technical expertise required in the oncology market.

"Using Innovex services also gives us both flexibility and scalability in our future sales force deployment."

The project will be overseen by a joint steering committee of representatives from PharmaMar and Innovex.

About Innovex

Innovex is the sales and marketing unit of Quintiles Transnational Corp. Innovex is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Innovex operates in multiple geographies and ensures that high quality sales solutions can be provided where the customer needs them -- locally, regionally and across multiple countries. For more information, visit http://www.innovex.com.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com.

About PharmaMar

PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar has five novel compounds: Yondelis(r) has received Authorization for Commercialization from the European Commission for advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or for patients who are unsuited to receive these agents. Yondelis(r) is also in phase III for ovarian cancer and phase II for prostate, breast and pediatric cancers. Aplidin(r), Kahalalide F, Zalypsis(r) and PM02734 are in clinical trials. PharmaMar also has a rich pipeline of preclinical candidates, and a strong R&D program.


'/>"/>
SOURCE Innovex
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ForceLogix, Innovex Win Sales Operational Performance Award
2. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Enzyme promotes fat formation
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):